It was a good quarter. Estimates raised. This makes little sense
Just sayin'. Everything in biotech seems slightly down today. Maybe the sell off is not specific to AEGR. Fundamentals seem very much intact. Rollout going well. Company is exceeding expectations. Stock will look cheap based on 2014 and 2015 EPS which likely are solidifying.
Who cares when the company is profitable??? Doesn't matter. Think long term. This stock should not be trading on the timing of a few pennies here or there. What is the long term earning potential for the company? Very significant, in my opinion. Remember there are not that many shares outstanding (about 30MM). They own Juxtapid outright. If they earn $100MM applying a 30% margin, that would be $1.00 in EPS. Anyone remember what the peak sales of the drug are forecast at??? Exactly.